Janux Therapeutics Inc

NASDAQ:JANX  
11.66
-0.55 (-4.50%)
Products

Janux Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Janx007

Published: 05/31/2022 12:16 GMT
Janux Therapeutics Inc (JANX) - Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for Janx007, a Psma-tractr for Metastatic Castration-resistant Prostate Cancer.
Janux Therapeutics Inc - Phase 1 Clinical Study of Psma-tractr (janx007) Expected to Initiate in 2h 2022.